[
  {
    "ts": null,
    "headline": "Assessing AbbVie’s Value After 25.5% Rally and Oncology Growth Moves in 2025",
    "summary": "If you own AbbVie stock or are thinking about adding it to your portfolio, you’ve probably noticed the ups and downs lately. After an impressive 25.5% gain so far this year, shares have cooled off a bit over the past week, dropping 1.5%. Looking at the big picture, AbbVie’s long-term run has been nothing short of remarkable, with a 189.5% climb over five years. Moves like these naturally make investors wonder if the current price reflects genuine growth potential, or if the market is simply...",
    "url": "https://finnhub.io/api/news?id=1a0507a83b1390245a6b9a171e963c95eb941f12e3279dcc3e50dd3a8554bab5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761779259,
      "headline": "Assessing AbbVie’s Value After 25.5% Rally and Oncology Growth Moves in 2025",
      "id": 137263656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "If you own AbbVie stock or are thinking about adding it to your portfolio, you’ve probably noticed the ups and downs lately. After an impressive 25.5% gain so far this year, shares have cooled off a bit over the past week, dropping 1.5%. Looking at the big picture, AbbVie’s long-term run has been nothing short of remarkable, with a 189.5% climb over five years. Moves like these naturally make investors wonder if the current price reflects genuine growth potential, or if the market is simply...",
      "url": "https://finnhub.io/api/news?id=1a0507a83b1390245a6b9a171e963c95eb941f12e3279dcc3e50dd3a8554bab5"
    }
  },
  {
    "ts": null,
    "headline": "The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday, November 19, 2025. This holiday honors the exceptional providers and valued patients who've contributed to the continued success of BOTOX® Cosmetic. As the biggest celebration of the year, BOTOX® Cosmetic Day champions those who count on the one and only BOTOX® Cosmetic by providing exclusive offers through Allē, the aesthetic loyalty program from Allergan Aes",
    "url": "https://finnhub.io/api/news?id=1a0db0601c45c56ac47260849be4cafadda3ba9fd6f8bdf59dc10e42faf68414",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761771600,
      "headline": "The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year",
      "id": 137263657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the seventh annual BOTOX® Cosmetic Day will take place on Wednesday, November 19, 2025. This holiday honors the exceptional providers and valued patients who've contributed to the continued success of BOTOX® Cosmetic. As the biggest celebration of the year, BOTOX® Cosmetic Day champions those who count on the one and only BOTOX® Cosmetic by providing exclusive offers through Allē, the aesthetic loyalty program from Allergan Aes",
      "url": "https://finnhub.io/api/news?id=1a0db0601c45c56ac47260849be4cafadda3ba9fd6f8bdf59dc10e42faf68414"
    }
  },
  {
    "ts": null,
    "headline": "Trump Administration Eases Approval Process for Biosimilar Drugs",
    "summary": "The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs.  Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval.  Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.",
    "url": "https://finnhub.io/api/news?id=287d0ef9221eb67b40d545c1c2c65b5ad514b01e5cb4170bea5b384dd8b7b8fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761764918,
      "headline": "Trump Administration Eases Approval Process for Biosimilar Drugs",
      "id": 137260309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive for drugmakers to develop biosimilar medicines, the copycat versions of off-patent biologic drugs.  Under the new draft guidance, FDA would no longer require all biosimilar manufacturers to run clinical trials of their drugs as a condition of approval.  Instead, the FDA says it will look at analytical studies that can show whether or not the biosimilar matches the branded drug it seeks to copy.",
      "url": "https://finnhub.io/api/news?id=287d0ef9221eb67b40d545c1c2c65b5ad514b01e5cb4170bea5b384dd8b7b8fe"
    }
  },
  {
    "ts": null,
    "headline": "Assessing AbbVie (ABBV) Valuation as Shares Approach Recent Highs and Outpace Sector Returns",
    "summary": "AbbVie (ABBV) has seen its stock tick slightly lower this week, with shares down 0.2% today but still up 3% over the past month. Investors are weighing these recent moves along with long-term double-digit returns. See our latest analysis for AbbVie. Zooming out, AbbVie’s share price return over the past year highlights the stock’s strong upward momentum, and when you factor in dividends, its total shareholder return hits an impressive 24% for the year. That outperformance, combined with...",
    "url": "https://finnhub.io/api/news?id=cd4660f1636b74be1e3b71b64652efc575d831bc1e45b3e72c66e4475ca01abc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761750818,
      "headline": "Assessing AbbVie (ABBV) Valuation as Shares Approach Recent Highs and Outpace Sector Returns",
      "id": 137258519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) has seen its stock tick slightly lower this week, with shares down 0.2% today but still up 3% over the past month. Investors are weighing these recent moves along with long-term double-digit returns. See our latest analysis for AbbVie. Zooming out, AbbVie’s share price return over the past year highlights the stock’s strong upward momentum, and when you factor in dividends, its total shareholder return hits an impressive 24% for the year. That outperformance, combined with...",
      "url": "https://finnhub.io/api/news?id=cd4660f1636b74be1e3b71b64652efc575d831bc1e45b3e72c66e4475ca01abc"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo",
    "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4",
    "url": "https://finnhub.io/api/news?id=66d4d02319a131e39ea79f2737d62eb057659e3ca3973341c9c89e3060de6767",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739860,
      "headline": "AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo",
      "id": 137247893,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily in adult and adolescent patients living with non-segmental vitiligo (NSV).1 NSV, the most common form of vitiligo (occurring in over 90% of patients), is characterized by symmetrical and bilateral white patches on both sides of the body.2-4",
      "url": "https://finnhub.io/api/news?id=66d4d02319a131e39ea79f2737d62eb057659e3ca3973341c9c89e3060de6767"
    }
  },
  {
    "ts": null,
    "headline": "With 74% institutional ownership, AbbVie Inc. (NYSE:ABBV) is a favorite amongst the big guns",
    "summary": "Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...",
    "url": "https://finnhub.io/api/news?id=704a0a532e906f0aadbbac57af7974caf4a0ca6a9192668a3eb74a831dd31575",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739213,
      "headline": "With 74% institutional ownership, AbbVie Inc. (NYSE:ABBV) is a favorite amongst the big guns",
      "id": 137247894,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Key Insights Significantly high institutional ownership implies AbbVie's stock price is sensitive to their trading...",
      "url": "https://finnhub.io/api/news?id=704a0a532e906f0aadbbac57af7974caf4a0ca6a9192668a3eb74a831dd31575"
    }
  },
  {
    "ts": null,
    "headline": "Best Dividend Kings: October 2025",
    "summary": "Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Read more here.",
    "url": "https://finnhub.io/api/news?id=e88d07ba5881f7fac15aa768a04affc18b86c74fac7aa9fc28bbd4c57b8e173a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761714686,
      "headline": "Best Dividend Kings: October 2025",
      "id": 137246617,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2148089915/image_2148089915.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Read more here.",
      "url": "https://finnhub.io/api/news?id=e88d07ba5881f7fac15aa768a04affc18b86c74fac7aa9fc28bbd4c57b8e173a"
    }
  }
]